Investigating biomarkers in ovarian cancer
Official title: Prognostic and Predictive Biomarkers in Ovarian Cancers
Run by Gustave Roussy, Cancer Campus, Grand Paris · NCT03010124 · Data updated 2026-11-12
This study is trying to find specific markers in ovarian cancer patients' samples to see how they relate to treatment success and to improve personalized treatment options.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 350 (estimated) |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Villejuif, Val de Marne) |
| Status | Recruiting |
| Started | September 26, 2016 |
| Main results expected | September 2030 |
| Study ends | September 2032 |
| Registry record updated | March 20, 2026 |
| Trial ID | NCT03010124 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include new patients diagnosed with ovarian cancer or previously treated patients with available tumor samples who are experiencing disease progression.
✕Probably not a fit
Patients who do not meet the inclusion criteria or those with coagulation abnormalities that prevent biopsy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to analyze tumor samples, ascites, blood, and other biological materials from patients with ovarian cancer to identify prognostic and predictive biomarkers. By correlating these markers with patient outcomes, the research seeks to understand how genetic diversity in ovarian cancer affects chemotherapy resistance. Additionally, the study will perform functional assays on freshly collected samples to validate potential therapeutic targets. The goal is to enhance treatment strategies based on individual patient profiles.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for ovarian cancer patients.
How similar studies have gone: Other studies have shown promise in identifying biomarkers for ovarian cancer, suggesting that this approach could yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. New patient with a diagnosis of OC, or 2. Previously treated patient with frozen or formalin fixed paraffin embedded primary tumour sample available that can be retrieved by the center presenting with progressive disease, and consenting to CT guided biopsy of relapsed disease, or 3. Previously treated patient with frozen or formalin fixed paraffin embedded primary tumour sample available that can be retrieved by the center scheduled for surgery for relapsed disease. 4. Signed informed consent 5. Age ≥ 18 6. Patient affiliated to a social security regimen or beneficiary of the same Exclusion Criteria: 1. Patients who do not fit the inclusion criteria and those who refuse an antitumoral treatment; 2. Coagulation abnormalities that contra-indicates the biopsy
Where it's running
-
Gustave Roussy
Villejuif, Val de Marne, France Recruiting
Study contacts
- Study coordinator: Alexandra LEARY, MD
- Email: alexandra.leary@gustaveroussy.fr
- Phone: +33 (0)1 42 11 43 89
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.